FDA Purple Book · Reference family
brodalumab (Siliq)
brodalumab is an FDA-licensed reference biologic from Bausch Health Ireland, Limited. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2017
Reference approved
Reference product
351(a)BLA 761032
Siliq brodalumab
Bausch Health Ireland, Limited
- Approved
- Feb 15, 2017
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for brodalumab, in chronological order.
Reference approval
Approval date of the reference brodalumab product.
9 yr 5 mo ago
Frequently asked questions
Are there biosimilars approved for brodalumab (Siliq)?
No 351(k) biosimilars or interchangeable biosimilars referencing brodalumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.